Akeso says Phase III HARMONi-2 trial shows ivonescimab lifts overall survival vs pembrolizumab in PD-L1-positive NSCLC

• Akeso disclosed positive overall survival results for ivonescimab versus pembrolizumab in first-line PD-L1-positive advanced NSCLC from Phase III HARMONi-2.
• Results were published on the WCLC website on Sept. 13, 2026; full data are scheduled for oral presentation on Sept. 15.
• Ivonescimab extended survival versus pembrolizumab, with benefits broadly consistent across key patient subgroups.
• Safety remained broadly comparable between study arms, with no new safety concerns highlighted.
• Akeso positioned the readout as supporting ivonescimab’s competitive profile versus standard PD-1 therapy in the first-line setting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609130259PR_NEWS_USPR_____CN46519) on September 13, 2026, and is solely responsible for the information contained therein.